Cutting-edge CAR engineering: beyond T cells

Simple item page
dc.contributor.authorChocarro de Erauso, Luisa
dc.contributor.authorBlanco, Ester
dc.contributor.authorFernández Rubio, Leticia
dc.contributor.authorArasanz Esteban, Hugo
dc.contributor.authorBocanegra Gondán, Ana Isabel
dc.contributor.authorEchaide Górriz, Míriam
dc.contributor.authorGarnica, Maider
dc.contributor.authorRamos, Pablo
dc.contributor.authorPiñeiro Hermida, Sergio
dc.contributor.authorVera García, Ruth
dc.contributor.authorKochan, Grazyna
dc.contributor.authorEscors Murugarren, David
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2023-04-24T07:23:44Z
dc.date.available2023-04-24T07:23:44Z
dc.date.issued2022
dc.date.updated2023-04-24T06:48:08Z
dc.description.abstractChimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks efficacy in solid tumours, possibly because engineered T cells become inactive within the immunosuppressive tumour microenvironment (TME). In the TME, cells of the myeloid lineage (M) are among the immunosuppressive cell types with the highest tumour infiltration rate. These cells interact with other immune cells, mediating immunosuppression and promoting angiogenesis. Recently, the development of CAR-M cell therapies has been put forward as a new candidate immunotherapy with good efficacy potential. This alternative CAR strategy may increase the efficacy, survival, persistence, and safety of CAR treatments in solid tumours. This remains a critical frontier in cancer research and opens up a new possibility for next-generation personalised medicine to overcome TME resistance. However, the exact mechanisms of action of CAR-M and their effect on the TME remain poorly understood. Here, we summarise the basic, translational, and clinical results of CAR-innate immune cells and CAR-M cell immunotherapies, from their engineering and mechanistic studies to preclinical and clinical development.en
dc.description.sponsorshipThe OncoImmunology group is funded by the Spanish Association against Cancer (AECC) [grant number PROYE16001ESCO]; Instituto de Salud Carlos III (ISCIII)-FEDER project grants [grant numbers FIS PI17/02119, FIS PI20/00010, COV20/00000, TRANSPOCART ICI19/00069]; a Biomedicine Project grant from the Department of Health of the Government of Navarre [grant number BMED 050-2019]; strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Project Horizon 2020 Improved Vaccination for Older Adults (ISOLDA; ID: 848166); Crescendo Biologics Ltd. supported the OncoImmunology group for the development and testing of PD-1 and LAG-3 bispecifics.en
dc.format.mimetypeapplication/pdfen
dc.format.mimetypeapplication/zipen
dc.identifier.citationChocarro, L., Blanco, E., Fernández-Rubio, L., Arasanz, H., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Piñeiro-Hermida, S., Vera, R., Kochan, G., & Escors, D. (2022). Cutting-edge car engineering: Beyond t cells. Biomedicines, 10(12), 3035. https://doi.org/10.3390/biomedicines10123035en
dc.identifier.doi10.3390/biomedicines10123035
dc.identifier.issn2227-9059
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/45147
dc.language.isoengen
dc.publisherMDPIen
dc.relation.ispartofBiomedicines, 2022, 10(12), 1-17en
dc.relation.projectIDinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058/
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines10123035
dc.rights© 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCAR-macrophageen
dc.subjectCAR-monocyteen
dc.subjectCAR-myeloiden
dc.subjectCAR-NKen
dc.subjectImmunotherapyen
dc.subjectTumour microenvironmenten
dc.titleCutting-edge CAR engineering: beyond T cellsen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationfe5c362e-3c0c-4edb-aa2e-0de27c815ad2
relation.isAuthorOfPublication.latestForDiscoveryfe5c362e-3c0c-4edb-aa2e-0de27c815ad2

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Chocarro_CuttingEdge.pdf
Size:
1013.98 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Chocarro_CuttingEdge_MatCompl.zip
Size:
32.81 KB
Format:
ZIP
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak